Adaptimmune Therapeutics PLC reports results for the quarter ended in September - Earnings Summary

Adaptimmune Therapeutics

08/11/2022 16:00

* Adaptimmune Therapeutics PLC  ADAP.OQ  reported a
quarterly
adjusted loss of 24 cents​​ per share for the quarter ended in
September. The mean expectation of seven analysts for the
quarter was for a loss of 24 cents per share.
    * Revenue rose 482.5% to $7.01 million from a year ago;
analysts
expected $4.04 million. 
    * Adaptimmune Therapeutics PLC's reported EPS for the
quarter was
a loss of 24 cents​.
    * The mean earnings estimate of analysts had risen by
about 0.7%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * Adaptimmune Therapeutics PLC shares had risen by 54.4%
this
quarter and lost 55.7% so far this year.
    * The company reported a quarterly loss of $41.42 million.
    * Wall Street's median 12-month price target for Adaptimmune
Therapeutics PLC is $3.50 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 4
"hold" and 1 "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
8 at 04:00 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.24          -0.24          Met
 Jun. 30 2022      -0.25          -0.28          Missed
 Mar. 31 2022      -0.22          -0.30          Missed
 Dec. 31 2021      0.14           -0.24          Missed